Projects

Project Description

a) Background:

A randomized placebo controlled trial to assess the safety and efficacy of spironolactone on cardiovascular outcomes among patients with end-stage renal disease

b) Objectives:

• Primary: To determine if spironolactone reduces cardiac morbidity and mortality for patients treated with chronic dialysis.
• Secondary: To assess the safety and other efficacy of spironolactone in patients treated with chronic dialysis

c) Sample size: Global - 2750 / India - 500

d) Study update:

• Global – 3565- Run in and 2,538 –Randomized
• In India-471- Run in and 312- Randomised

g) Publication status (Name & year): Published in Lancet, 2025

h) Publication link:

Michael Walsh, David Collister, Martin Gallagher, Patrick B Mark, Janak R de Zoysa, Jessica Tyrwhitt, Karthik Tennankore, Gilmar Reis, Denis Xavier, Wen J Liu, Li Zuo, Amanda Y Wang, Camilo Félix, Laura Sola, Mustafa Arici, Russell Villanueva, Vivekanand Jha, Dalton Précoma, Christian G Rabbat, Sheik Sulthan Alavudeen, Atiya R Faruqui, Mavel López-Flecher, Lonnie Pyne, Ron Wald, Fei Yuan, Kumar Balasubramanian, Shun Fu Lee, Alena Kuptsova, Courtney Christou, PJ Devereaux, et al….“Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial”, The Lancet; 2025/8/16.